Floatz logo

121 assets in Urinary Bladder Carcinoma

Therapeutic assets addressing Urinary Bladder Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Mnpr-101-Dfo-89Zr
Urinary Bladder Carcinoma
Monopar TherapeuticsP1C (39)
Mnpr-101-Pcta-177Lu
Urinary Bladder Carcinoma
Monopar TherapeuticsP1C (39)
Monoclonal Antibody Trk-950
Urinary Bladder Carcinoma
Toray Industries, IncP1C (39)
Naptumomab Estafenatox
Urinary Bladder Carcinoma
NeoTX Therapeutics Ltd.P1C (39)
Obinutuzumab
Urinary Bladder Carcinoma
NeoTX Therapeutics Ltd.P1C (39)
Onm-501
Urinary Bladder Carcinoma
OncoNano Medicine, Inc.P1C (39)
pds01adc
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P1C (39)
pf-07263689
Urinary Bladder Carcinoma
PfizerP1C (39)
pf-07921585
Urinary Bladder Carcinoma
PfizerP1C (39)
pf-08046876
Urinary Bladder Carcinoma
PfizerP1C (39)
Pimitespib
Urinary Bladder Carcinoma
Brown UniversityP1C (39)
Tbi-1301
Urinary Bladder Carcinoma
University Health Network, TorontoP1C (39)
Tumor Antigen Loaded Autologous Dendritic Cells
Urinary Bladder Carcinoma
Sichuan UniversityP1C (39)
Zirconium Zr 89-Dfo-Ys5
Urinary Bladder Carcinoma
Robert Flavell, MD, PhDP1C (39)
Immunotherapic Bifunctional Fusion Protein Comprised Of A Fully Human Igg1 Monoclonal Antibody (Avelumab) Against Human Programmed Death-Ligand 1 (Pd-L1) Fused To The Soluble Extracellular Domain Of Transforming Growth Factor-.Beta. (Tgf-.Beta.) Receptor Ii, Which Acts As A Tgf-.Beta. Trap
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P1C (38)
Recombinant L-Ifn Adenovirus
Urinary Bladder Carcinoma
Shanghai Fengxian District Central HospitalEarly P1C (36)
Hepatitis A Vaccine
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2C (35)
Blood, Whole
Urinary Bladder Carcinoma
UNC Lineberger Comprehensive Cancer CenterN/AD (30)
Sasanlimab
Urinary Bladder Carcinoma
PfizerP1D (28)
Cabozantinib
Urinary Bladder Carcinoma
National Cancer Institute (NCI)P2NR ()
Showing 101 to 121 of 121 assets
PreviousPage 3 of 3Next